Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality

BACKGROUND: Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials. METHODS: This was the final day 28 comparat...

Descripción completa

Detalles Bibliográficos
Autores principales: Olender, Susan A, Walunas, Theresa L, Martinez, Esteban, Perez, Katherine K, Castagna, Antonella, Wang, Su, Kurbegov, Dax, Goyal, Parag, Ripamonti, Diego, Balani, Bindu, De Rosa, Francesco G, De Wit, Stéphane, Kim, Shin-Woo, Diaz, George, Bruno, Raffaele, Mullane, Kathleen M, Lye, David Chien, Gottlieb, Robert L, Haubrich, Richard H, Chokkalingam, Anand P, Wu, George, Diaz-Cuervo, Helena, Brainard, Diana M, Lee, I-Heng, Hu, Hao, Lin, Lanjia, Osinusi, Anu O, Bernardino, Jose I, Boffito, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244650/
https://www.ncbi.nlm.nih.gov/pubmed/34282406
http://dx.doi.org/10.1093/ofid/ofab278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244650/
https://www.ncbi.nlm.nih.gov/pubmed/34282406
http://dx.doi.org/10.1093/ofid/ofab278

Ejemplares similares